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Cancer stem cells (CSCs) are a subpopulation of
tumor cells suggested to be critical for tumor mainte-
nance, metastasis, and therapeutic resistance. Pro-
spective identification and targeting of CSCs are
therefore priorities for the development of novel
therapeutic paradigms. Although CSC enrichment
has been achieved with cell surface proteins includ-
ing CD133 (Prominin-1), the roles of current CSC
markers in tumor maintenance remain unclear.
We examined the glioblastoma stem cell (GSC) peri-
vascular microenvironment in patient specimens to
identify enrichment markers with a functional sig-
nificance and identified integrin a6 as a candidate.
Integrin a6 is coexpressed with conventional GSC
markers and enriches for GSCs. Targeting integrin
a6 in GSCs inhibits self-renewal, proliferation, and
tumor formation capacity. Our results provide evi-
dence that GSCs express high levels of integrin a6,
which can serve not only as an enrichment marker
but also as a promising antiglioblastoma therapy.
INTRODUCTION
Cancers are complex biological systems that contain neoplastic
and nonneoplastic cells along with vasculature, inflammatory
cells, and associated stroma (Hanahan and Weinberg, 2000).
In the neoplastic compartment, some tumors contain cellular
fractions capable of initiating tumors similar to the parental tumor
when transplanted into a secondary site. This fraction of cells,
referred to as cancer stem cells (CSCs), tumor-initiating cells,
or tumor-propagating cells, has been found in many tumors
(Reya et al., 2001) including brain cancers (Bao et al., 2006a,
2006b; Galli et al., 2004; Hemmati et al., 2003; Ignatova et al.,
2002; Singh et al., 2003, 2004; Taylor et al., 2005; Yuan et al.,
2004). Gliobastoma multiforme (GBM) is the most common
and lethal primary brain tumor with less than 3% 5 year survival
rate (Stupp et al., 2005). Recent experimental evidence from our
laboratory and others has suggested the CSC population can bea potential therapeutic target. Glioblastoma stem cells (GSCs)
are relatively radioresistant (Bao et al., 2006a) and chemoresist-
ant (Liu et al., 2006). GSCs activate a number of key stem cell
signaling pathways, including Akt, bone morphogenetic pro-
tein, c-myc, hypoxia response, Notch, and Sonic Hedgehog
(Bar et al., 2007; Eyler et al., 2008; Fan et al., 2006; Li et al.,
2009; Piccirillo et al., 2006; Wang et al., 2008b).
Critical to GSC research is their prospective identification and
isolation from tumor tissue. Many studies have relied on the
enrichment of GSCs based on expression of the cell surface
protein CD133 (prominin-1) (see review by Bidlingmaier et al.,
2008), which has also been used as a selection marker for neural
stem cells (Uchida et al., 2000). However, CD133 faces limita-
tions as indicated by recent reports that show that CD133-nega-
tive GBM cells can form tumors (Beier et al., 2007; Joo et al.,
2008; Wang et al., 2008a) and the expression of CD133 may
be cell cycle regulated (Jaksch et al., 2008). These issues under-
score the need for additional markers to identify GSCs, of which
several have been proposed (L1CAM, A2B5, CD15) (Bao et al.,
2008; Ogden et al., 2008; Read et al., 2009; Son et al., 2009).
An alternative strategy for the identification of GSC markers
and possible therapeutic targets could be based on examination
of the perivascular microenvironment in which GSCs reside
(Calabrese et al., 2007). Extracellular matrix (ECM) proteins are
key structural components of the perivascular niche and regulate
normal stem cell and tumor proliferation and migration (Gilbert-
son and Rich, 2007). The ECM modulates cell behavior via the
heterodimer integrin cell surface receptors, which consist of
a and b subunits (Hynes, 2002). Integrins direct development
as demonstrated by the severe phenotypes displayed by many
integrin knockout models (Schmid and Anton, 2003), including
brain phenotypes (Georges-Labouesse et al., 1998; Graus-Porta
et al., 2001). Recently, selection based on integrins has been
used to enrich for normal neural stem/progenitor cells (Lathia
et al., 2007b; Hall et al., 2006), as well as CSCs from the breast
(Vaillant et al., 2008) and prostate (Patrawala et al., 2007).
Of particular interest to stem cell biology has been integrin a6,
the receptor for the ECM protein laminin, which forms hetero-
dimers with integrin b1 or b4. Integrin a6 is highly expressed in
embryonic, hematopoeitic, and neural stem cells (Fortunel
et al., 2003). In the brain, laminins and integrin a6b1 regulate
neural stem cell growth (Hall et al., 2008) and play a pivotal
role in maintaining adhesion to the ventricular zone, ensuringCell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc. 421
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Figure 1. Integrin a6 Is Expressed in Human GBM Cells and Localized to the Perivascular Compartment
Immunostaining of GBM surgical biopsies (HP 08-0444, HP 06-033, HP 08-0445) demonstrates that integrin a6 (green) is expressed in the perivascular compart-
ment (double stained with CD31 in red, A, B) and is coexpressed with CD133 (red, C, D). Blood vessels marked with an asterisk, regions of interest marked with
a white arrow, and enlarged regions of interest marked with yellow arrow and shown in (A0)–(D0). All nuclei counterstained with Hoechst in blue. Scale bars repre-
sent 50 mm. Flow cytometry analysis (E) indicates that integrin a6 is expressed in a fraction of cells in primary surgical GBMbiopsies 18 hr after isolation (CCF1585)
or after short-term culture (CCF1518) with varying overlap with CD133 expression.
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GBM Stem Cells Regulated by Integrin Alpha 6proper neural stem cell division (Loulier et al., 2009). Laminin is
also a key component in culturing relatively pure adherent GSC
cultures, suggesting a critical role for the laminin-integrin rela-
tionship in GSC maintenance (Fael Al-Mayhani et al., 2009;
Pollard et al., 2009). With the importance of integrin a6 in neural
stem cells, the perivascular localization of GSCs enriched in
ECM, and use of laminin to propagate GSC cultures, we hypoth-
esized that integrin a6may serve as a functional marker of GSCs.
RESULTS
Integrin a6 Marks the Glioblastoma Perivascular Niche
Although previous studies have evaluated integrin a6 in normal
astrocytes (Aloisi et al., 1992; Paulus et al., 1993) and gliomas422 Cell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc.(Gingras et al., 1995; Vitolo et al., 1996), the relationship of integ-
rin a6-expressing GBM cells with the vasculature remains
unknown. To evaluate this relationship, we assessed GBM sur-
gical biopsy specimens labeled with antibodies against integrin
a6 and CD31, an endothelial cell marker. In concordance with
the perivascular niche of GSCs (Calabrese et al., 2007), we
detected high integrin a6 expression levels in these regions
with infrequent coexpression with CD31 (Figures 1A and 1B),
suggesting that these cells were not endothelial cells. 60% of
integrin a6-positive GBM cells were located within 5 mm of
a blood vessel as compared to only 10%of total tumor cells (Fig-
ure S1A available online). Integrin a6 and CD133 were coex-
pressed in perivascular regions (Figures 1C and 1D). Similar peri-
vascular coexpression patterns for integrin a6 and nestin were
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Figure 2. Integrin a6 Is Coexpressed with CD133 in GSCs
(A) Quantitative PCR from tumor xenografts (T3359, T4105, T4302, T4597, T0166) indicates that in CD133-enriched GSC-enriched populations, integrin a6 is also
highly expressed in comparison to CD133-depleted nonstem glioma cells (n = 3, ± SEM; *p < 0.05; **p < 0.001).
(B) Reverse-transcription PCR analysis demonstrates that integrin a6 and the GSC marker Olig2 are highly expressed in GSCs isolated from T4302, T4597, and
T0166 tumor xenografts. NC, negative control (no cDNA added).
(C) Flow cytometry analysis indicates that integrin a6 expression overlaps with CD133 expression in tumor xenografts (T3691, T0322).
(D) Immunostaining analysis from tumor xenograft cells (T3359) immediately after CD133 enrichment show coexpression of CD133+ cells with integrin a6 (red) and
GSC markers CD133 (green) and Olig2 (green, nuclei counterstained in blue with Hoechst). CD133 cells show limited GSC or integrin a6 marker expression.
Scale bar represents 10 mm.
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GBM Stem Cells Regulated by Integrin Alpha 6also evident (Figures S1B and S1C). These findings were con-
firmed in freshly isolated GBM surgical biopsies, with a frac-
tion of integrin a6-positive cells (1.1% and 15.9%, CCF1585,
CCF1966), and dual flow cytometry analysis with CD133 indi-
cated an overlap in expression that ranged from 0.1% to
11.3% of the total population (Figure 1E). These data demon-
strate that a fraction of GBM cells express integrin a6 located
in the perivascular niche.
GSCs Express High Levels of Integrin a6
In GBM surgical biopsies, integrin a6 and CD133 expression
levels were correlated. To evaluate GSC expression of integrina6, GSCs were derived from human specimens amplified
in vivo as previously described (Bao et al., 2006a, 2006b,
2008; Li et al., 2009). Functional assays to define GSCs included
self-renewal assays, expression of stem cell markers, and tumor
propagation. GSCs expressed significantly higher levels of integ-
rin a6 mRNA compared to matched nonstem glioma cells by
quantitative real-time PCR (Figure 2A). Reverse-transcription
PCR confirmed differential integrin a6 mRNA expression in
GSCs with a similar pattern in expression of Olig2, another puta-
tive GSCmarker (Figure 2B). To evaluate the expression of integ-
rin a6 and CD133 at the cellular level, we performed both flow
cytometry and single-cell immunoflourescence. We detectedCell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc. 423
T
3
3
5
9
T
3
6
9
1
T
4
3
0
2
Figure 3. Integrin a6 Cosegregates with CD133+ GSCs
Immunostaining analysis of cryosections from tumorspheres generated from GSC-enriched populations (T3359, T3691, T4302) show the peripheral region
(yellow arrow, enlarged inset in bottom right corner) that appears to correlate with high integrin a6 expression and the inner region (white arrow), which is low
in integrin a6 expression. Photomicrographs show integrin a6 (green) is coexpressed with GSC markers Olig2 (red, A, D, G), CD133 (red, B, E, H), and nestin
(red, C, F, I). All nuclei counterstained with Hoechst in blue. Scale bars represent 10 mm.
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GBM Stem Cells Regulated by Integrin Alpha 6variations in the expression levels of integrin a6 and CD133,
but the cellular populations expressing both antigens strongly
overlapped (Figure 1C; Table S1). Integrin a6 was expressed in
a greater percentage of GSCs as compared to nonstem glioma
cells (Figure S2). To correlate the expression of integrin a6 with
other GSCmarkers, we analyzedGSCs immediately after enrich-
ment by immunofluorescence. Integrin a6, CD133, and Olig2
were coexpressed in the GSCs but in the non-GSC cell fraction
(Figure 2D). These results show that integrin a6 is enriched in the
GSC population.
Integrin a6 Expression Cosegregates with GSC
Marker Expression
To further assess the expression of integrin a6 with regard to
other GSC markers, we cultured CD133-enriched GSCs as
tumorspheres by using previously reported proliferation con-
ditions (Lee et al., 2006a). Cryosectioned spheres contained
cellular populations that coexpress integrin a6 and GSCmarkers424 Cell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc.Olig2 (Figures 3A, 3D, and 3G), CD133 (Figures 3B, 3E, and 3H),
and nestin (Figures 3C, 3F, and 3I). Integrin a6 forms functional
dimers with integrin b1 or b4, but we did not detect integrin b4
expression (data not shown), so we focused on integrin b1
expression. Integrin a6-expressing cells in tumorspheres ex-
pressed the integrin b1 coreceptor with proximal extracellular
laminin ligand expression supporting the presence of a fully
active integrin signaling unit (Figure 4). Although leukemic stem
cells display a quiescent phenotype, we and others have found
that GSCs are proliferative. Indeed, integrin a6-positive cells in
tumorspheres expressed the M-phase marker phospho-histone
H3 (pH3), suggesting a cycling GSC (Figures S3A–S3C). Finally,
we assessed the relationship between differentiation and cell
survival of the integrin a6 population by using the neuronal
marker Map2 (Figures S3D–S3F) and the terminal deoxynucleo-
tidyl transferase dUTP nick end labeling (TUNEL) assay
(Figure S3G), which detects DNA fragmentation as an indicator
of apoptosis. We found that nonstem glioma cells and apoptotic
T3359 T3691 T4302
Figure 4. Integrin a6 Segregates with Coreceptor Integrin b1 and Ligand, Laminin
Photomicrographs from tumorspheres generated from GSC-enriched populations (T3359, T3691, T4302) show integrin a6 (green) is expressed with coreceptor
integrin b1 (red, A, B, C) and ligand laminin (red, D, E, F) in the peripheral region (yellow arrow), but not the inner region (white arrow). All nuclei counterstained with
Hoechst in blue. Scale bars represent 50 mm.
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GBM Stem Cells Regulated by Integrin Alpha 6cells do not express high levels of integrin a6. Collectively, these
data show that integrin a6 cosegregates with GSC markers as
well as the appropriate coreceptor and ligand.
Cell Selection Based on Integrin a6 and CD133
Expression Enriches for Cells with In Vitro
GSC Properties
CD133 has not been absolutely informative in segregating tumor
propagation, requiring the development of additional CSC
markers and suggesting that CD133 cells with GSC properties
may be identified with other markers. Based on this background,
we assessed the utility of integrin a6 selection alone or in com-
bination with CD133 to enrich for GSCs by using fluorescence-
activated cell sorting (FACS). As demonstrated in Figure 1,
double labeling of tumor specimens with integrin a6 and CD133
yields four populations. Cells from the CD133+;integrin a6hi and
CD133;integrin a6hi quadrants proliferated more than cells
negative for integrin a6 (Figures 5A and 5B). Tumorsphere forma-
tion assays, which are associated with self-renewal but are not
an absolute indicator of self-renewal, showed that CD133+;inte-
grin a6hi and CD133;integrin a6hi formed spheres with signifi-
cantly greater efficiency than cells negative for integrin a6 (Fig-
ures 5C and 5D). These results demonstrate that integrin a6
expression is informative for cells with a higher propensity
to proliferate and form tumorspheres in both CD133+ and
CD133 populations.
CD133 expression is not always detectable in all tumors and
therefore, we assessed the ability for integrin a6 to enrich forGSCs. We evaluated a tumor (D320MG) in which there is little
CD133 expression (Figure S4A) and divided the expression level
of integrin a6 into three compartments (low, medium, and high;
Figure S4B). Cells that were integrin a6hi (medium and high)
displayed greater cell proliferation profile (Figure S4C) and
increased tumorsphere formation than did integrin a6lo cells
(Figure S4D). Cells with the highest level of integrin a6 expression
(representing the top 50% of the integrin a6 expression) prolifer-
ated the most and formed secondary spheres with the greatest
efficiency. These results demonstrate that integrin a6 can be
used to enrich for cells with in vitro GSC properties in a tumor
that expresses little to no detectable levels of CD133.
Next we assessed the ability of integrin a6hi and integrin a6lo
cells to undergo self-renewal in an in vitro setting. Tumor
specimens were enriched or depleted based on integrin a6
expression levels and plated at single-cell clonal density. Signif-
icantly more tumorspheres formed from the integrin a6hi popula-
tion (Figures 5E and 5F). These results suggest that the majority
of the cells that undergo self-renewal are integrin a6hi and
confirm our data that demonstrated that integrin a6hi cells (with
or without high levels of CD133) are more likely to self-renew.
We additionally queried whether there were differences between
the CD133+;integrin a6hi and CD133;integrin a6hi cell popula-
tions. Tumorspheres were generated from each cell population
and CD133 expression was assessed. CD133+ parental popula-
tions had greater CD133 expression than did CD133;integrin
a6hi parental populations (T08-0387: 13.5% integrin a6hi/
CD133, 25.1% CD133+, 47% reduction; T3359: 11.3% integrinCell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc. 425
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Figure 5. Selection of Cells Based on Integ-
rin a6 Expression Enriches for a Population
that Display GSC Properties
After GSC enrichment based on integrin a6 and
CD133 expression, each cell population (black,
CD133/integrin a6lo; green, CD133+/integrin
a6lo; red, CD133/integrin a6hi; blue, CD133+/
integrin a6hi) had a different growth profile. Cell
titer assays demonstrated increased growth in in-
tegrin a6hi cells isolated from T0322 (A) or T3359
(B) cells. **p < 0.01 with ANOVA comparison to
CD133/integrin a6lo cells at the same time point;
###p < 0.001 with ANOVA comparison of CD133+/
integrin a6hi cells to either CD133+/integrin a6lo or
CD133/integrin a6hi cells at the same time point.
In tumorsphere formation assays for T3359 (C)
and T3691 (D) cells, selection for CD133 and
integrin a6 increased the number of tumor-
spheres per well. ***p < 0.001 with ANOVA com-
parison to CD133/integrin a6lo cells; ###p <
0.001 with ANOVA comparison of CD133+/
integrin a6hi cells to either CD133+/integrin a6lo
or CD133/integrin a6hi cells; &&p <
0.01 and &&&p < 0.001 with ANOVA comparison
to CD133+/integrin a6lo cells. GBM cells (from
tumor specimens T3359, T4302) were sorted
at a single cell per well based on integrin a6
expression. Graphs (E, F) indicate that cells
selected from the integrin a6hi population (orange
bar) formed tumorspheres at a significantly higher
frequency than cells from the integrin a6lo popu-
lation (black bar, ***p < 0.001). (G, H) Kaplan-
Meier survival curves demonstrate decreased
survival when cells high in integrin a6 expression
are transplanted into the right frontal lobe of
immunocompromised mice (yp < 0.067 for 1000
CCF1966 cells; **p < 0.01 for 500 T08-0387 cells
[p = 0.0051] with log-rank analysis of survival
curves). Error bars represent ± SEM.
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GBM Stem Cells Regulated by Integrin Alpha 6a6hi/CD133, 30.5% CD133+, 63% reduction; data not shown).
These results demonstrate the utility of integrin a6 enrichment
for GSCs, both in the presence and absence of CD133 expres-
sion. Another aspect of GSC biology is the ability to possess
multilineage differentiation capacity. GBM cells were selected
based on elevated integrin a6 expression level, expanded briefly,
and then differentiated. Cells that originated from integrin a6hi
cells were capable of differentiating into all three CNS lineages:
neurons, astrocytes, and oligodendrocytes (Figure S5). These
studies confirm the ability of integrin a6hi cells to both self-renew
and differentiate into CNS lineages, demonstrating that they
possess stem cell-like properties.426 Cell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc.Cell Selection Based on Integrin a6
Expression Levels Enriches
forCellswith InVivoGSCProperties
The final property of GSCs, and arguably
the most critical, is the ability to prop-
agate secondary tumors. To evaluate
whether integrin a6 expression was
indicative of a GSC phenotype, we en-
riched or depleted two separate tumorsbased on integrin a6 expression via FACS and performed
in vivo limiting dilution transplantation assays. Cells enriched
in integrin a6 expression (integrin a6hi) formed tumors at
a significantly higher frequency and shorter time to tumor
initiation than cells with integrin a6lo expression (Figures 5G
and 5H; Table S2). In addition, fewer integrin a6hi cells were
required to initiate tumors that grew with a shorter latency
compared to integrin a6lo cells (p = 0.0021; Table S2). These
results, along with the tumorsphere formation and differentia-
tion studies, demonstrate that cells that possess high levels
of integrin a6 are capable of fulfilling the functional definition
of a GSC.
Cell Stem Cell
GBM Stem Cells Regulated by Integrin Alpha 6Integrin a6 Is Critical to GSC Self-Renewal
and Tumor Formation
Given that integrin a6 is enriched in GSCs and that selection of
bulk tumor cells based on integrin a6 expression yields cells
with GSC properties, we hypothesized that integrin a6 functions
to promote GSC maintenance. Lentivirus delivered short hairpin
RNA (shRNA) constructs were designed against integrin a6
(shRNA 1 targeting exon 14 and shRNA 2 targeting exon 2).
We validated integrin a6 knockdown in GSCs by FACS (Fig-
ure S6A). Targeting integrin a6 inhibited GSC cell growth (Figures
6A and 6B) and abrogated tumorsphere formation (Figure 6C;
Figures S6B and S6C). To determine the cellular mechanism,
we assessed cell cycle progression and survival. GSCs trans-
duced with shRNA against integrin a6 underwent cell cycle
arrest and increased cell death. Cell cycle analysis showed an
increase in the G1 fraction and a decrease in S phase fractions
for cells targeted with integrin a6 shRNA (Figures S6D and
S6E). The decrease in S phase was confirmed with 5-ethynyl-
20-deoxyuridine (EdU) incorporation (Figure 6D). Cell death
increased upon integrin a6 targeting as assessed by caspase
3/7 activation (Figure 6F; Figures S6F and S6G) and DNA frag-
mentation (Figure 7E) assays. Interestingly, targeting integrin
a6 in the CD133;integrin a6hi cell fraction produced a similar
phenotype with decreased tumorsphere formation (Figure S6H),
decreased cell growth (Figure S6I), an increase in G1 and
decrease in S phase of the cell cycle (Figure S6J), and increased
cell death (Figures S6K and S6L), suggesting that integrin a6
contributes to cell growth regardless of CD133 expression.
These results demonstrate that targeting of integrin a6 in
CD133+;integrin a6hi and CD133;integrin a6hi cells results in
a compromised GSC phenotype.
Next, we evaluated whether disruption of integrin a6 function
decreases tumor formation. To achieve this, we infected GSCs
(T3359 CD133+ cells cultured short term) with a lentivirus deliv-
ering shRNA directed against integrin a6 or a nontargeting
control and then transplanted either 1000 or 5000 cells into the
brains of immunocompromised mice. Mice bearing integrin a6
shRNA GSCs showed significantly reduced tumor formation
(Figure 6G) and greater median survival (Table S3) as compared
with nontargeting control GSCs (representative tumor shown in
Figure 6H). These results suggest that integrin a6 is a regulator
of tumor growth and functional knockdown of this signaling
pathway reduces tumor formation.
Integrin function has been disrupted with a number of blocking
antibodies and peptides, some of which have entered into
clinical trials. To interrogate a potentially translatable targeting
of integrin a6, we utilized an integrin a6 blocking antibody to
evaluate integrin a6 function in GSCs. GSCs treated with the
blocking antibody displayed reduced cell proliferation (Figures
7A and 7B) and tumorsphere formation (Figure 7C) compared
with an isotype control antibody. In addition, we transplanted
GSCs treated with the blocking antibody into the brains of
immunocompromised mice. Mice bearing cells incubated with
an isotype control antibody showed consistent tumor formation
while mice bearing cells incubated with the blocking antibody
displayed greater tumor latency (p = 0.0027 for T4597 and p =
0.0143 for T4302; Figure 7D; Table S4). As a final confirmation
of the clinical relevance of integrin a6, we interrogated an
in silicoGBMpatient database and found that integrin a6 expres-sion inversely correlates with survival (p = 0.0129; Figure S7).
Taken together, our results show that integrin a6 expression is
elevated in GSCs, can be used for GSC enrichment, and regu-
lates aspects of their phenotype.
DISCUSSION
In this study, we have identified an ECM receptor, integrin a6, as
being highly expressed in the GSC population. We observed
that selection based on integrin a6 expression alone, or in
combination with CD133, results in an enrichment of the GSC
population from bulk tumor. These data also demonstrate that
other markers can be used along with CD133 to enrich for
GSCs (previously reported for L1CAM [Bao et al., 2008], A2B5
[Ogden et al., 2008], and CD15 [Son et al., 2009]). In addition,
we show that the level of integrin a6 expression alone can be
used as a measure GSC potential, which has also been used
for normal stem cells (Hall et al., 2006). Our findings demonstrate
that integrin a6 can be used to enrich for GSCs as well as serve
as a potential therapeutic target and underscores the need to
further evaluate of CSC niches in order to identify additional
markers and therapeutic cites.
The prospective isolation of GSCs from bulk tumors remains
a critical, unresolved issue. GBMs display remarkable heteroge-
neity so it is unlikely that a single marker or even a collection
of markers (an immunophenotype) will absolutely enrich for
GSCs. However, our data suggests that integrin a6 does inform
the GSC phenotype. In addition, integrin a6 contributes to tumor
cell proliferation, survival, self-renewal, and in vivo growth. The
role of integrin a6 is complex as we detect heterogeneity in the
expression of both CD133 and integrin a6 and GSCs may
express both CD133 and integrin a6 or possibly integrin a6 alone
as integrin a6 single-positive cell populations can proliferate
and self-renew. This is not a unique challenge in solid tumor
stem cell markers because the uniformity of information con-
tained in CSC markers remains an unresolved question in the
CSC field. For example, in breast cancer, the CD44hiCD24lo
immunophenotype enriches for CSCs as does ALDHhi, yet these
cellular pools only overlap to a minor degree in many tumors
(Ginestier et al., 2007). Even within a single tumor, different pools
of CSCs may be present (Piccirillo et al., 2009). It is therefore
likely that tumors have variability not only in the fraction of
CD133+ and integrin a6hi cells but also in how these populations
overlap and the potential that some variances in how they mark
GSCs. The generalizability of our studies may be supported by
a combination of data from GBM surgical biopsy specimens
that have been previously demonstrated to be an accurate
model of the human disease. We have amplified some tumors
as xenografts, which we and others have shown tomaintain their
tumorgenic potential and relative marker expression (Bao et al.,
2006a; Shu et al., 2008; Son et al., 2009). The correlation
between integrin a6 and CD133 expression observed in xeno-
grafts by flow cytometry and immunostaining from T3359 and
T3691 specimens was also observed in the original GBM biop-
sies (Figures S1D and S1E).
The perivascular localization of integrin a6 provides additional
substantiation to the importance of the vasculature GSCmainte-
nance. Our studies add an additional mechanism in the interplay
betweenCSCs and the tumor vasculature. Previous studies haveCell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc. 427
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Figure 6. Integrin a6 Knockdown Results in a Reduction in the GSC Phenotype
(A and B) Knockdown of integrin a6 via two separate lentiviral shRNA constructs results in a decreased cell proliferation profile as assessed by the cell titer assay
in T3691 (A) and T4121 (B) xenograft tumor cells. ***p < 0.001 with ANOVA comparison to nontargeting shRNA at the same time point; ##p < 0.01 with ANOVA
comparison of shRNA1 to shRNA2 at the same time point.
(C) Quantification of the number of tumorspheres per well and representative pictures of tumorspheres demonstrates potential self-renewal was also impaired in
GSC targeted with the lentivial shRNA constructs in T4302 cells. *p < 0.05 with ANOVA comparison to nontargeting control.
(D) EdU incorporation demonstrates a decrease in proliferative capacity T4302 cells via both shRNA constructs (***p < 0.001 with ANOVA comparison to non-
targeting control, ###p< 0.001 with ANOVA comparison to shRNA1).
(E and F) Knockdown of integrin a6 also increases cell death as assessed by a DNA fragmentation assay (E) on T4302 xenograft tumor cells (M1, 1 kb ladder; Un,
uninfected control; NT, nontargeting shRNA control; sh1, shRNA1; sh2, shRNA2; Ctrl, staurosporine control; M2, 100 bp ladder). Cell death was also confirmed
with a caspase 3/7 assay (F) on T4121 xenograft tumor cells (***p < 0.001 with ANOVA comparison to nontargeting control; ###p < 0.001 with ANOVA comparison
to shRNA1).
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Figure 7. Integrin a6 Blocking Antibody Results in a Reduction in the GSC Phenotype
(A and B) This decrease in GSC proliferation was also seen with a blocking antibody to integrin a6 in T3691 (A) and T4121 (B) xenograft tumor cells in a concen-
tration-dependent manner as compared to an isotype control antibody. **p < 0.01 with ANOVA comparison to isotype control at the same time point.
(C) Tumorsphere formation is also inhibited by addition of the blocking antibody in T3359 xenograft tumor cells as shown by quantification of the number of tumor-
spheres per well and in representative images. *p < 0.01.
(D) Kaplan-Meier survival curve demonstrating increased survival when GSCs are incubated with the blocking antibody. 1000 integrin a6+/CD133 GSCs
incubated with either a control or integrin a6 blocking antibody for 5 days and intracranially transplanted into the right frontal lobe of immunocompromised
mice. **p < 0.01 with log-rank analysis of survival curves.
Error bars represent ± SEM.
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GBM Stem Cells Regulated by Integrin Alpha 6demonstrated that growth factors (Bao et al., 2006b) and cell-to-
cell signaling (Calabrese et al., 2007) are regulators of GSCs, and
we now demonstrate that the ECM present in the perivascular
compartment maintains GSC via integrin a6. The ECM provides
both structural and instructive cues to normal neural stem
cells (Lathia et al., 2007a) within the CNS. Several reports have
suggested that ECM structures originating from blood vessels
in the adult neural stem cell germinal zones are critical in
preserving their maintenance through serving as a reservoir for
growth factors (Kerever et al., 2007). The amplification of limited
growth factor concentrations is an underappreciated function
of the ECM and in GBMs may play a vital role in trapping the
secreted factors aiding in the preservation of GSCmaintenance.
A potential clinical significance of our findings is derived from
the ability of targeting integrin a6 in GSCs via blocking antibodies
or lentivirus-delivered shRNA to compromise self-renewal and(G) Kaplan-Meier survival curve demonstrate increased survival when integrin a6
infected with integrin a6 shRNA targeting constructs or nontargeting control wer
mice. *p < 0.05; **p < 0.01 by log-rank analysis of survival curves.
(H) Representative light micrograph showing H&E staining for a control nontarget
migrating edges, and secondary tumors, insets displayed below.
Error bars represent ± SEM.tumor-initiation potential. In vivo studies demonstrated that
integrin a6 blockade increased tumor latency and survival, sug-
gesting that integrin a6 is playing a role in tumor propagation,
and in some instance tumor initiation. Dissecting the impact
of integrin a6 on tumor initiation versus propagation is a critical
question but is not possible with current in vivo assays. Our data
are consistent with previous reports showing that CSC-specific
therapies may reduce tumor growth without an absolute termi-
nation of tumor growth (Hoey et al., 2009) and underscore
the development of multimodal therapies that integrate both
convention and CSC therapeutic approaches. Our results further
suggest that RNA interference approaches for the integrins may
require further development because we were unable to com-
pletely silence integrin a6 expression as shown by flow cytome-
try analysis (Figure S6A). In addition, the tumors that formed
from integrin a6 lentivirus-targeted GSCs showed expressionis targeted with shRNA in comparison to a nontargeting control. 1000 GSCs
e intracranially transplanted into the right frontal lobe of immunocompromised
ing integrin a6 1000 cell tumor showing characteristic bilateral tumor location,
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GBM Stem Cells Regulated by Integrin Alpha 6of integrin a6 (Figure S6M), suggesting the lentiviral knockdown
of integrin a6 is not completely efficient or may be silenced.
One limitation of integrin targeting alone may be the long half
life of the protein (hours to days, depending on the context).
RNA inference may be useful in combinatorial treatment para-
digms with neutralizing antibodies or conventional cytotoxic
therapies, such as radiation and temozolomide. Another pos-
sible therapeutic combination strategy would target the vascula-
ture with antiangiogenics (e.g., bevacizumab) (Bao et al., 2006b)
or vascular disruptive agents because integrin a6 has recently
been reported to have a combined effect with VEGF in human
brain microvascular cells (Lee et al., 2006b). To maximize a ther-
apeutic index, the design of such therapies must take into
consideration the integrin a6 expression throughout the brain,
even if the integrin targeting is confined to a focal region. Integrin
a6 is highly expressed by neural stem cells in rodents (Campos
et al., 2004; Lathia et al., 2007a) and humans (Hall et al., 2006).
In the adult murine brain, integrin a6 expression has been
reported in the neural stem cell compartment adjacent to the
lateral ventricles (Shen et al., 2008) and a detailed analysis
suggests that the proliferating cells express integrin a6 as do
the neural stem cell upon activation (I. Kazanis, J.D.L., C.
ffrench-Constant, unpublished observation). In addition, integrin
a6 is expressed by embryonic and adult astrocytes, with levels
being modulated in a cytokine-dependent manner (Aloisi et al.,
1992; Paulus et al., 1993).
Although the exact pathway to which integrin a6 is driving
the GSC phenotype is yet to be determined, it is likely to involve
common downstream molecules of integrins such as Akt and
c-myc, which we and others recently showed were also critical
in GSC maintenance (Eyler et al., 2008; Wang et al., 2008b;
Zheng et al., 2008). Aside from maintenance, disrupted integrin
a6 could expose a survival requirement for GSC. It was recently
shown in neural stem cells that addition of laminin to the culture
media increased neurosphere formation and survival (Hall et al.,
2008). Ablation of integrin a6may compromise cell survival path-
ways in GSCs. Taken together, these data underscore the impor-
tance of integrin signaling within GBMs because targeting other
integrins have shown promise (e.g., Cilengitide, an inhibitor of in-
tegrins avb3 and avb5, is currently in clinical trials) (Reardon
et al., 2008) and suggest that GSCmay preferentially have higher
levels in integrins.
In summary, we show that GSCs have elevated levels of integ-
rin a6, which can be used as an enrichment strategy alone or in
combination with CD133. In addition, targeting integrin a6 has
profound consequences on the GSC phenotype and may
provide a therapeutic target for GBMs.EXPERIMENTAL PROCEDURES
GSC Isolation
GSCs were isolated from primary surgical GBM biopsy specimens in accor-
dance with protocols approved by the Duke University Medical Center or
Cleveland Clinic Foundation Institutional Review Boards. GSCs were used
immediately after dissociation or after transient xenograft passage in immuno-
compromisedmice. Cells were sorted intomarker-positive and -negative pop-
ulations via a CD133/2-APC conjugated antibody (293C3, Miltenyi Biotech) or
an integrin a6-FITC antibody (55735, BD Biosciences) by fluorescence-acti-
vated cell sorting (FACS) or magnetic bead separation based on CD133 as
previously described (Eyler et al., 2008; Wang et al., 2008b).430 Cell Stem Cell 6, 421–432, May 7, 2010 ª2010 Elsevier Inc.PCR Analyses
Real-time PCR analysis was done as previously described (Wang et al.,
2008b). Real-time PCR was performed on an ABI 7900HT system via SYBR-
Green Mastermix (SA Biosciences). The threshold cycle (CT) values for each
gene were normalized to expression levels of b-actin. The primers used
were as follows: Integrin a6, ATTCTCATGCGAGCCTTCAT, GGAAACACAGTC
ACTCGAACC; b-actin, AGAAAATCTGGCACCACACC, AGAGGCGTACAGG
GATAGCA.
Reverse-transcription PCR was according to manufacturer’s protocols.
The sequences of the PCR primers are as follows: Integrin a6, CTCGGCAC
AGCAACCTTGAACATT, TGAGCATGGATCTCAGCCTTGTGA; Olig2, ATCTG
GGTCAATCCACACCCTCTT, ACAGCTTAGCATTGCGCACTTACC.
Immunofluorescence
For immunostaining analyses, surgical GBMbiopsy specimens were fixedwith
4% PFA for 10 min at room temperature. Cells or sections were blocked with
a PBS-based solution containing 10% normal goat serum (Sigma) and 0.1%
triton x-100 (Sigma). Sections or cells were incubated overnight with the
appropriate primary antibody at 4C and then washed with PBS three times
prior to incubation with the appropriate secondary antibody for 45 min at
room temperature. Prior to coverslip application, nuclei were counterstained
with Hoechst and imaging done with a Leica SP-5 confocal microscope as
described previously (Wang et al., 2008b).
In Vivo Tumor Initiation Analysis
In vivo tumor initiation analyses were done with BALB/c nu/nu mice under
a Cleveland Clinic Foundation Institutional Animal Care and Use Committee-
approved protocol as previously described (Bao et al., 2006b; Wang et al.,
2008b). All transplanted mice were maintained for 100 days or until develop-
ment of neurologic signs.
Statistical Analysis
Values are reported as the mean ± the standard error. GraphPad Instat 3 Soft-
ware (GraphPad Software, Inc.) was used to determine statistical significance
with either two-tailed Student’s t test or ANOVA as indicated. Significance
testing of survival was performed by log-rank analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
doi:10.1016/j.stem.2010.02.018.
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